Gamida Cell Ltd. (NASDAQ:GMDA) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET
Company Participants
Heather DiVecchia - Chief of Staff
Michele Korfin - Chief Operating Officer and Chief Commercial Officer
Ronit Simantov - Chief Medical Officer and Chief Scientific Officer
Shai Lankry - Chief Financial Officer
Conference Call Participants
Eric Musonza - Evercore
Edward Tenthoff - Piper Sandler
Gilbert Blum - Needham and Company
Matthew Cross - Alliance Global Partners
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell’s Conference Call for the First Quarter 2022 Financial Results. My name is Carmen and I will be your Operator for today’s call. Please be advised that this call is being recorded at Gamida Cell’s request.
Now, I would like to introduce your host for today’s conference, Heather DiVecchia, Gamida Cell’s Chief of Staff. Please go ahead.
Heather DiVecchia
Thank you, Carmen and good morning, everyone. Welcome to today’s call during which we will provide an update on the Company and review our financial results for the first quarter of 2022. Earlier this morning, we issued a press release summarizing our financial results and progress across the Company, which is available on our website at website at www.gamidacell.com.
Please note that unfortunately, our Chief Executive Officer, Julian Adams is unable to join us this morning due to contracting COVID-19. Company operations are unaffected and Julian has advised us that his symptoms are improving, and he expects to recover shortly.
With that here with me on our call today are Michele Korfin, our Chief Operating Officer and Chief Commercial Officer; Ronit Simantov, our Chief Medical Officer and Chief Scientific Officer; and Shai Lankry, Chief Financial Officer.
During this call, we may make Forward-Looking Statements about our future expectations and plans, including in respect to the timing of initiation and progress of, and data reported from the clinical trials of our product candidates, anticipated regulatory filings, including the submission of the BLA for Omidubicel to the FDA, commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidate, including GDA-201 and Omidubicel, and our expectations regarding our projected cash to be used for operating activities and cash runway.
Our actual results may differ materially from what we project today due to a number of important factors, including the impacts of COVID-19 pandemic on our operations, the scope, progress and expansion of our clinical trials and cost impact thereof, clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and the endeavor of building a business around such product candidates, as well as those considerations described in the Risk Factors section of our most recent annual report on Form 10-K and other filings that we make with the SEC from time-to-time.